AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)

RecruitingPhase 4Ages 18 Years - anyAllHospital Universitario de Fuenlabrada
💬

In plain words

What the trial is, and whether it could suit you

The aim of this study is to assess whether there are differences in PERITONEAL RECURRENCE in patients with Colon Cancer Peritoneal Metastases treated with complete surgical resection and systemic chemotherapy, with (Group 1) or without (Group 2) HIPEC with Mitomycin-C.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Histologically confirmed colon adenocarcinoma, except signet ring cell carcinomas (those with \> 50% of the tumor composed of these cells, which comprise only 1% of all colon adenocarcinomas). 2. Absence of previously treated or current extraperitoneal metastases, including distant lymphadenopathy (retroperitoneal, mediastinal, etc), liver metastases, or lung metastases (ruled out by PET-scan in case of doubt). 3. Synchronous or metachronous peritoneal metastasis of mild to moderate volume, with a PCI ≤ 20 (Appendix 2) (intraoperative confirmation). 4. Macroscopically complete surgical cytoreduction CCS-0 (intraoperative confirmation). 5. Treatment with perioperative systemic chemotherapy (SCT), before and/or after surgical procedure. 6. Age\> 18 years. 7. Acceptable anesthetic/surgical risk: ASA 1-3 (Appendix 3), ECOG 0-1 (Appendix 4). No severe alterations in hematological, renal, cardiac, pulmonary or hepatic function (operable patients). 8. Information to the patient and signing of a study-specific informed consent. Exclusion Criteria: 1. Peritoneal carcinomatosis of any other origin, particularly rectal cancer or appendicular adenocarcinoma, or signet ring cell colon cancer on histology. 2. No intraoperative confirmation of peritoneal disease (PCI 0). Likewise, cases of perianastomotic (local) or lymph node (locoregional) recurrences will be excluded. 3. High volume peritoneal disease with a PCI\> 20 (intraoperative evaluation). 4. Concurrent or previously treated extraperitoneal disease. 5. Disease progression during preoperative chemotherapy, if received. 6. Patients previously treated with HIPEC. 7. History of other cancers (except cutaneous basal cell carcinoma or cervix carcinoma in situ) in the 5 years prior to entry into the study. 8. Patients included in another first-line clinical trial for the studied disease. 9. Pregnancy (or suspicion of it) or lactation period. 10. Emergency surgical intervention for obstruction or perforation of a primary tumour with synchronous PM (although rescue and secondary CRS + HIPEC after emergency surgery of the primary tumour are acceptable if inclusion criteria are fulfilled). 11. Persons deprived of liberty or under legal or administrative supervision. 12. Inability to understand the nature of the intervention, the risks, benefits, expected evolution and the need to undergo periodic medical examinations, either for geographical, social or psychological reasons.
💊

What it tests

  • complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes
  • complete cytoreductive surgery without HIPEC
📍

Where

31 sites
Hospital General Universitario de Elche
Elche, Spain
Hospital Universitario Torrecárdenas
Almería, Spain
Complejo Hospitalario Universitario de Badajoz
Badajoz, Spain
Hospital Sant Joan Despi Moises Broggi
Sant Joan Despí, Spain
Hospital General Universitario de Castellón
Castellon, Spain
Consorcio Hospitalario Provincial de Castellón
Castellon, Spain
Hospital General Universitario de Ciudad Real
Ciudad Real, Spain
Hospital Universitario Reina Sofía
Córdoba, Spain

…and 23 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy